Rein Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein Therapeutics, formerly known as Aileron Therapeutics Inc., is based in AUSTIN, Texas.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-62.88M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 27.34 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.11 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -510.35% |
| Return on Assets (Trailing 12 Months) | -40.77% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.90 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.90 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.63 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 26.29M |
| Free Float | 24.95M |
| Market Capitalization | $36.54M |
| Average Volume (Last 20 Days) | 0.23M |
| Beta (Past 60 Months) | 1.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |